MEDI3506

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

8 competitors in Lupus

#DrugCompanyPhaseTrials

1

Olumiant

Eli Lilly

Approved

—2

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—3

Saphnelo

AstraZeneca

Phase 3

14

Farxiga

AstraZeneca

Phase 3

15

Xarelto

WWim Janssens

Phase 3

16

LUNSUMIO

Roche

Phase 2

17

MEDI3506

AstraZeneca

Phase 3

18

Orencia

Bristol-Myers Squibb

Preclinical

—9

Cyclophophamide

AAllogene Therapeutics

Phase 1

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

COPD1 trial

Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

Completed·AstraZeneca·Phase 1·NCT03096795·88 enrolled

Atopic Dermatitis1 trial

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

Completed·AstraZeneca·Phase 2·NCT04212169·148 enrolled

Asthma1 trial

Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma

Completed·AstraZeneca·Phase 2·NCT04570657·250 enrolled

Immunogenicity1 trial

Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

Completed·AstraZeneca·Phase 1·NCT05070312·39 enrolled

Lupus1 trial

GLOW-1: Efgartigimod in Systemic Lupus

Recruiting·Argenx·Phase 3·NCT04170543·450 enrolled

Details

Drug Info

Related News